<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03906292</url>
  </required_header>
  <id_info>
    <org_study_id>Fascination</org_study_id>
    <secondary_id>2018‐002256‐33</secondary_id>
    <nct_id>NCT03906292</nct_id>
  </id_info>
  <brief_title>Frontline Asciminib Combination in Chronic Phase CML</brief_title>
  <acronym>CMLXI</acronym>
  <official_title>Frontline Asciminib Combination in Chronic Phase CML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Ernst, PD Dr. med.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult male and female patients with newly diagnosed Philadelphia chromosome positive (Ph+)
      and/or BCR-ABL1 positive CML can be included in the study until 3 months after diagnosis. A
      &lt;4 week pretreatment with hydroxyurea is permitted. Patients treated for &lt;6 weeks with
      nilotinib 300 mg BID, imatinib 400 mg QD, or dasatinib 100 mg QD are eligible for recruitment
      and will be allocated to the respective cohort. All patients must provide written informed
      consent to be enrolled in the trial. Cohorts were designed to allow assessment of QD and BID
      asciminib based combinations to optimize quality of life and compliance. Patients will not be
      randomized. In general, cohorts will be filled consecutively. Asciminib therapy will be
      commenced 12 weeks after start of nilotinib, imatinib or dasatinib and after recovery of
      hematopoiesis. Referred patients already treated with imatinib, nilotinib or dasatinib will
      remain on the initial drug and will be allocated to the respective cohort.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the dramatic progress made over the past decade with TKIs in the treatment of CML,
      allogeneic stem cell transplant remains the only proven curative therapy. To achieve cure or
      benefit from treatment-free remissions with pharmacologically-based therapies, it is
      estimated that patients will likely need to achieve a sustained reduction in tumor burden
      corresponding to a deep molecular response of at least 4 logs (MR4). Currently, only 30.8% of
      patients achieve a deep molecular response after 12 months of treatment with single agent
      nilotinib.

      The development of the novel and potent BCR-ABL1 allosteric inhibitor, asciminib, presents an
      opportunity to assess the effect of a different mechanism of inhibition of BCR-ABL1 in the
      first-line treatment of CML to enhance speed of response and to increase the patient
      population benefitting from deep molecular response. Dosing a combination of asciminib with
      an ATP-site inhibitor also has the potential to prevent the emergence of resistance due to
      point mutations being acquired in one of the binding sites.

      The safety, tolerability and pharmacokinetic profile of asciminib as a single agent and in
      combination with either nilotinib or imatinib or dasatinib was assessed in a phase-I study.
      At the doses chosen here, all three combination treatments were well tolerated.

      Since in all patient cohorts the standard of care therapy will remain the backbone of initial
      therapy, there is no reason to expect an efficacy problem with the combination therapies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2019</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>4 parallel cohorts</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>deep molecular response (Rate of MR4)</measure>
    <time_frame>at month 12 after Start of Therapy</time_frame>
    <description>Achievement of deep molecular response (MR4) throught standardized testing of BCR-ABL-transcript Levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>molecular response (MMR and MR4.5)</measure>
    <time_frame>at and by 6, 12, 18 and 24 months after Start of Therapy</time_frame>
    <description>Achievement of deep molecular response throught standardized testing of BCR-ABL-transcript levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>at and by baseline, 3, 6, 12, 15, 18, 21 and 24 months after Start of Therapy</time_frame>
    <description>Incidence of adverse events grade 1-5 and 3-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>at month 24 after Start of Therapy</time_frame>
    <description>Progression free survival at the end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at month 24 after Start of Therapy</time_frame>
    <description>Overall survival at the end of the study</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Asciminib 60mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard therapy of Imatinib 400 mg QD and asciminib 60 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asciminb 20 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard therapy of Nilotinib 300 mg BID and asciminib 20 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asciminib 40 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard therapy of Nilotinib 300 mg BID and asciminib 40 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asciminib 80 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard therapy of Dasatinib 100 mg QD and asciminib 80 mg QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>Imatinib 400 mg QD and asciminib 60 mg QD</description>
    <arm_group_label>Asciminib 60mg QD</arm_group_label>
    <other_name>Imatinib 400 mg QD and asciminib 60 mg QD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib 300 mg</intervention_name>
    <description>Nilotinib 300 mg BID and asciminib 20 mg BID or 40 mg QD</description>
    <arm_group_label>Asciminb 20 mg BID</arm_group_label>
    <arm_group_label>Asciminib 40 mg QD</arm_group_label>
    <other_name>Nilotinib 300 mg BID and asciminib 20 mg BID or 40 mg QD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Dasatinib 100 mg QD and asciminib 80 mg QD</description>
    <arm_group_label>Asciminib 80 mg QD</arm_group_label>
    <other_name>Dasatinib 100 mg QD and asciminib 80 mg QD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asciminib</intervention_name>
    <description>Asciminib</description>
    <arm_group_label>Asciminb 20 mg BID</arm_group_label>
    <arm_group_label>Asciminib 40 mg QD</arm_group_label>
    <arm_group_label>Asciminib 60mg QD</arm_group_label>
    <arm_group_label>Asciminib 80 mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients with diagnosis of CP-CML with cytogenetic confirmation of the
             Ph+ chromosome [t(9;22)(q34;q11)].

          -  Ph-negative cases or patients with variant translocations who are BCR-ABL1 positive in
             multiplex PCR 35 will be also considered eligible.

          -  ECOG performance status of ≤2.

          -  Age ≥ 18 years old (no upper age limit is given)

          -  Serum levels of potassium, magnesium, total calcium within the normal limits (≥LLN
             [lower limit of normal] and ≤ULN [upper limit of normal]). Correction of electrolytes
             levels with supplements to fulfil enrolment criteria is allowed.

          -  AST and ALT ≤2.5 x ULN or 5.0 x ULN if considered due to leukemia

          -  Alkaline phosphatase ≤2.5 x ULN unless considered due to leukemia

          -  Total bilirubin ≤1.5 x ULN, except known Gilbert disease

          -  Serum creatinine ≤2 x ULN

          -  Written informed consent prior to any study procedures being performed.

        Exclusion Criteria:

          -  Allogeneic stem cell transplantation

          -  Known impaired cardiac function, including any of the following:

               -  Congenital long QT syndrome

               -  History of or presence of clinically significant ventricular or atrial
                  tachyarrhythmia

               -  QTc &gt;450 msec on screening ECG

               -  Myocardial infarction within 12 months prior to starting therapy

          -  Other clinical significant heart disease (e.g. unstable angina, congestive heart
             failure)

          -  Acute or chronic viral hepatitis with moderate or severe hepatic impairment
             (Child-Pugh scores &gt;6), even if controlled

          -  Other concurrent uncontrolled medical conditions (e.g., active or uncontrolled
             infections, acute or chronic liver and renal disease) that could cause unacceptable
             safety risks or compromise compliance with the protocol

          -  Impaired gastrointestinal function or disease that may alter the absorption of study
             drug (e.g., ulcerative disease, uncontrolled nausea, vomiting and diarrhea,
             malabsorption syndrome, small bowel resection or gastric by-pass surgery)

          -  Concomitant medications known to be strong inducers or inhibitors of the CYP450
             isoenzyme CYP3A4

          -  Patients who have undergone major surgery ≤2 weeks prior to starting study drug or who
             have not recovered from side effects of such therapy

          -  Patients who are pregnant or breastfeeding or women of reproductive potential not
             employing an effective method of birth control. Women of childbearing potential must
             have a negative serum pregnancy test within 14 days of study start. Post-menopausal
             women must be amenorrheic for at least 12 months in order to be considered of
             non-childbearing potential. Male and female patients must agree to employ an effective
             method of birth control throughout the study and for up to 2 weeks following
             discontinuation of study drug

          -  Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not
             mandatory)

          -  Known serious hypersensitivity reactions to asciminib, imatinib, nilotinib or
             dasatinib

          -  Patients with a history of another primary malignancy that is currently clinically
             significant or currently requires active intervention

          -  Patients unwilling or unable to comply with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Ernst, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Jena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Ernst, PD Dr. med.</last_name>
    <phone>+49 3641</phone>
    <phone_ext>9396670</phone_ext>
    <email>fascination@med.uni-jena.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Fabisch, Dr.</last_name>
    <phone>+49 3641</phone>
    <phone_ext>9396670</phone_ext>
    <email>fascination@med.uni-jena.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen Medizinische Klinik IV</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Crysandt, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vivantes Netzwerk für Gesundheit GmbH Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maike de Wit, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite Universitätsmeditin Berlin, Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp le Coutre, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lino Teichmann, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Bormann, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Hänel, PD Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Ordemann, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Krause, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.-Antonius-Hospital Eschweiler</name>
      <address>
        <city>Eschweiler</city>
        <zip>52249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Staib, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Göthert, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabian Lang, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cornelius Waller, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Ernst, PD Dr.</last_name>
      <phone>+49 3641</phone>
      <phone_ext>9324201</phone_ext>
      <email>thomas.ernst@med.uni-jena.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg-Nikolaus Franke, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres. Müller/ Kröning/ Jentsch-Ullrich/ Tietze/ Krogel</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Jentsch-Ullrich, PD Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68169</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Saußele, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Burchert, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brüderkrankenhaus St. Josef Paderborn</name>
      <address>
        <city>Paderborn</city>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Gaska, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Brüder Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Schenk, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank Stegelmann, PD Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 14, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Jena</investigator_affiliation>
    <investigator_full_name>Thomas Ernst, PD Dr. med.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

